

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 58

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–96) and Recommended (1–57) International Nonproprietary Names can be found in *Cumulative List No. 12, 2007* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 58

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–96) et recommandées (1–57) dans la *Liste récapitulative No. 12, 2007* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 58

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–96) y Recomendadas (1–57) se encuentran reunidas en *Cumulative List No. 12, 2007* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:

Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

alogliptinum

alogliptin

2-({6-[(3*R*)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl}methyl)benzonitrile


alogliptine

2-({6-[(3*R*)-3-aminopipéridin-1-yl]-3-méthyl-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl}méthyl)benzonitrile

alogliptina

2-({6-[(3*R*)-3-aminopiperidin-1-il]-3-metil-2,4-dioxo-3,4-dihidropirimidin-1(2*H*)-il}metil)benzonitrilo

C₁₈H₂₁N₅O₂



alvespimycinum

alvespimycin



(4*E*,6*Z*,8*S*,9*S*,10*E*,12*S*,13*R*,14*S*,16*R*)-19-[[2-(dimethylamino)ethyl]amino]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

alvespimycine

carbamate de (4*E*,6*Z*,8*S*,9*S*,10*E*,12*S*,13*R*,14*S*,16*R*)-19-[[2-(diméthylamino)éthyl]amino]-13-hydroxy-8,14-diméthoxy-4,10,12,16-tetraméthyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaén-9-yle

alvespimicina

carbamato de (4*E*,6*Z*,8*S*,9*S*,10*E*,12*S*,13*R*,14*S*,16*R*)-19-[[2-(dimetilamino)etil]amino]-13-hidroxi-8,14-dimetoxi-4,10,12,16-tetrametil-3,20,22-trioxi-2-azabíciclo[16.3.1]docosa-1(21),4,6,10,18-pentaén-9-ilo

**amifampridinum**

amifampridine


pyridine-3,4-diamine

amifampridine

pyridine-3,4-diamine

amifampridina

piridina-3,4-diamina

**balamapimodum**



balamapimod

4-({3-chloro-4-[(1-methyl-1*H*-imidazol-2-yl)sulfanyl]phenyl}amino)-6-methoxy-7-[4-(pyrrolidin-1-yl)piperidin-1-yl]quinoline-3-carbonitrile

balamapimod

4-({3-chloro-4-[(1-méthyl-1*H*-imidazol-2-yl)sulfanyl]phényl}amino)-6-méthoxy-7-[4-(pyrrolidin-1-yl)pipéridin-1-yl]quinoléine-3-carbonitrile

balamapimod

4-({3-cloro-4-[(1-metil-1*H*-imidazol-2-il)sulfaniil]fenil}amino)-6-metoxi-7-[4-(pirrolidin-1-il)piperidin-1-il]quinolina-3-carbonitrilo**bevirimat**

bevirimat


3β-(3-carboxy-3-methylbutanoyloxy)lup-20(29)-en-28-oic acid

bévirimat

acide 3β-(3-carboxy-3-méthylbutanoyloxy)lup-20(29)-én-28-oïque

bevirimat

ácido 3β-(3-carboxi-3-metilbutanoiloxy)lup-20(29)-en-28-oico

**carisbamatum**



carisbamate

(2*S*)-2-(2-chlorophenyl)-2-hydroxyethyl carbamate

carisbamate

carbamate de (2*S*)-2-(2-chlorophényl)-2-hydroxyéthyle

carisbamato

carbamato de (2*S*)-2-(2-clorofenil)-2-hidroxietilo**cevipabulinum**


cevipabulin

5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-*N*-[(1*S*)-1,1,1-trifluoropropan-2-yl][1,2,4]triazolo[1,5-*a*]pyrimidin-7-amine

cévipabuline

5-chloro-6-{2,6-difluoro-4-[3-(méthylamino)propoxy]phényl}-*N*-[(1*S*)-1,1,1-trifluoropropan-2-yl][1,2,4]triazolo[1,5-*a*]pyrimidin-7-amine

cevipabulina

5-cloro-6-à2,6-difluoro-4-[3-(metilamino)propoxi]fenil)-*N*-[(1*S*)-1,1,1-trifluoropropan-2-il][1,2,4]triazolo[1,5-*a*]pirimidin-7-amina**dalcetrapibum**

dalcetrapib


S-{2-[1-(2-ethylbutyl)cyclohexanecarboxamido]=phenyl} 2-methylpropanethioate

dalcétrapib

2-méthylpropanethioate de *S*-[2-[[[1-(2-éthylbutyl)=cyclohexanecarboxamido]phényle]

dalcetrapib

2-metilpropanotioato de *S*-[2-[[[1-(2-etilbutil)=ciclohexanecarboxamido]fenilo]

$C_{23}H_{35}NO_2S$ **firategrastum**

firategrast


(2S)-2-(2,6-difluorobenzamido)-3-[4'-(ethoxymethyl)-2',6'-dimethoxy-[1,1'-biphenyl]-4-yl]propanoic acid

firatégrast

acide (2S)-2-(2,6-difluorobenzamido)-3-[4'-(éthoxyméthyl)-2',6'-diméthoxy-[1,1'-biphényl]-4-yl]propanoïque

firategrast

ácido (2S)-2-(2,6-difluorobenzamido)-3-[4'-(etoximetil)-2',6'-dimetoxi-[1,1'-bifenil]-4-il]propanoico

 $C_{27}H_{27}F_2NO_6$ **giripladibum**


giripladib

4-{3-[5-chloro-1-(diphenylmethyl)-2-(2-{[2-(trifluoromethyl)=phenyl]methanesulfonamido}ethyl)-1*H*-indol-3-yl]propyl}benzoic acid

giripladib

acide 4-{3-[5-chloro-1-(diphénylméthyl)-2-(2-{[2-(trifluorométhyl)=phényl]méthanesulfonamido}éthyl)-1*H*-indol-3-yl]propyl}benzoïque

giripladib

ácido 4-{3-[5-cloro-1-(difenilmetil)-2-(2-{[2-(trifluorometil)fenil]=metanesulfonamido}etil)-1*H*-indol-3-il]propil}benzoico $C_{41}H_{36}ClF_3N_2O_4S$ 

imepitoinum


imepitoïn

1-(4-chlorophenyl)-4-(morpholin-4-yl)-1,5-dihydro-2*H*-imidazol-2-one

imépitoïne

1-(4-chlorophényl)-4-(morpholin-4-yl)-1,5-dihydro-2*H*-imidazol-2-one

imepitoïna

1-(4-clorofenil)-4-(morfolin-4-il)-1,5-dihidro-2*H*-imidazol-2-onaC₁₃H₁₄ClN₃O₂**isavuconazolum**


isavuconazole

4-{2-[(2*R*,3*R*)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1*H*-1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl}benzonitrile

isavuconazole

4-{2-[(2*R*,3*R*)-3-(2,5-difluorophényl)-3-hydroxy-4-(1*H*-1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl}benzonitrile

isavuconazol

4-{2-[(2*R*,3*R*)-3-(2,5-difluorofenil)-3-hidroxi-4-(1*H*-1,2,4-triazol-1-il)butan-2-il]-1,3-tiazol-4-il}benzonitriloC₂₂H₁₇F₂N₅OS**isavuconazonii chloridum**

isavuconazonium chloride


1-[(2*R*,3*R*)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-4-[(1*RS*)-1-[methyl-(3-[(methylamino)acetyloxy]methyl]pyridin-2-yl)carbamoyloxy]éthyl]-1,2,4-triazolium chloride

chlorure d'isavuconazonium

chlorure de 1-[(2*R*,3*R*)-3-[4-(4-cyanophényl)-1,3-thiazol-2-yl]-2-(2,5-difluorophényl)-2-hydroxybutyl]-4-[(1*RS*)-1-[méthyl-(3-[(méthylamino)acétyloxy]méthyl]pyridin-2-yl)carbamoyloxy]éthyl]-1,2,4-triazolium

cloruro de isavuconazonio

cloruro de 1-[(2*R*,3*R*)-3-[4-(4-cianofenil)-1,3-tiazol-2-il]-2-(2,5-difluorofenil)-2-hidroxiutil]-4-[(1*RS*)-1-[metil-(3-[(metilamino)acetiloxi]metil]piridin-2-il)carbamoiloxi]etil]-1,2,4-triazolium

**linacloctidum**



linacloctide

[9-L-tyrosine]heat-stable enterotoxin (*Escherichia coli*)-(6-19)-peptide

linacloctide

[9-L-tyrosine]entérottoxine thermostable (*Escherichia coli*)-(6-19)-peptide

linacloctida

[9-L-tirosina]enterotoxina termoestable (*Escherichia coli*)-(6-19)-péptido**litenimodum**

litenimod

P-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-thymidine

liténimod

P-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-thymidine

litenimod

P-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-timidina

 $C_{256}H_{322}N_{95}O_{129}P_{25}S_{25}$

(3'-5')d(*P*-thio) (T-A-A-A-C-G-T-T-A-T-A-A-C-
G-T-T-A-T-G-A-C-G-T-C-A-T)

managlinatum dialanetilum

managlinat dialanetil


diethyl *N,N'*-[5-[2-amino-5-(2-methylpropyl)-1,3-thiazol-4-yl]furan-2-ylphosphonyl]di-L-alaninate

managlinat dialanétíl

N,N'-[5-[2-amino-5-(2-méthylpropyl)-1,3-thiazol-4-yl]furan-2-ylphosphonyl]di-L-alaninate de diéthyle

managlinat dialanetilo

N,N'-[5-[2-amino-5-(2-metilpropil)-1,3-tiazol-4-il]furan-2-ilfosfonoil]=
di-L-alaninato de dietilo

 $C_{21}H_{33}N_4O_6PS$


masitinibum

masitinib


4-[(4-methylpiperazin-1-yl)methyl]-*N*-(4-methyl-3-[[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino]phenyl)benzamide

masitinib

4-[(4-méthylpipérazin-1-yl)méthyl]-*N*-(4-méthyl-3-[[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino]phényl)benzamide

masitinib

4-[(4-metilpiperazin-1-il)metil]-*N*-(4-metil-3-[[4-(piridin-3-il)-1,3-tiazol-2-il]amino]fenil)benzamida

 $C_{28}H_{30}N_6OS$


methylnaltrexonii bromidum


methylnaltrexone bromide

(17*S*)-17-(cyclopropylmethyl)-4,5 α -epoxy-3,14-dihydroxy-17-methyl-6-oxo-14 β -morphinanum bromide

bromure de méthylnaltrexone

bromure de (17*RS*)-17-(cyclopropylméthyl)-4,5 α -époxy-3,14-dihydroxy-17-méthyl-6-oxomorphinanum

bromuro de metilnaltrexona

bromuro de (17*RS*)-17-(ciclopropilmetil)-4,5 α -epoxi-3,14-dihidroxi-17-metil-6-oxomorfinanio $C_{21}H_{26}BrNO_4$ 

and epimer at N⁺
et l'épimère en N⁺
y el epímero al N⁺

naptumomabum estafenatoxum*

naptumomab estafenatox


immunoglobulin fragment, anti-[trophoblast glycoprotein (TPBG, 5T4)] monoclonal 5T4 gamma1 heavy chain fragment fusion protein [*Mus musculus* VH (5T4V14: H41>P, S44>G, I69>T, V113>G)-IGHG1_CH1] - [Glycyl-Glycyl-Prolyl] - superantigen SEA/E-120 (synthetic), non-disulfide linked with monoclonal 5T4 kappa light chain [*Mus musculus* V-KAPPA (5T4V18: F10>S, T45>K, I63>S, F73>L, T77>S, L78>V, L83>A)-IGKC]

naptumomab estafénatox

immunoglobuline fragment, anti-[glycoprotéine du trophoblaste (TPBG, 5T4)] protéine de fusion du fragment de la chaîne lourde gamma1 du monoclonal 5T4 [*Mus musculus* VH (5T4V14: H41>P, S44>G, I69>T, V113>G)-IGHG1_CH1]- [Glycyl-Glycyl-Prolyl] - superantigène SEA/E-120 (synthétique), associée de manière non covalente à la chaîne légère kappa du monoclonal 5T4 [*Mus musculus* V-KAPPA (5T4V18: F10>S, T45>K, I63>S, F73>L, T77>S, L78>V, L83>A)-IGKC]

naptumomab estafenatox

fragmento de inmunoglobulina, anti-[glicoproteína de trofoblasto (TPBG, 5T4)] proteína de fusión del fragmento de la cadena pesada gamma1 del monoclonal 5T4 [*Mus musculus* VH (5T4V14: H41>P, S44>G, I69>T, V113>G)-IGHG1_CH1] - [Glicil-Glicil-Prolil]- superantígeno SEA/E-120 (sintético), asociada no covalentemente a la cadena ligera kappa del monoclonal 5T4 [*Mus musculus* V-KAPPA (5T4V18: F10>S, T45>K, I63>S, F73>L, T77>S, L78>V, L83>A)-IGKC]



Heavy chain GGP toxin / Chaîne lourde GGP toxine / Cadena pesada GGP toxina

EVQLQQSGPD	LVKPGASVKI	SCKASGYSFT	GYMHVWKQS	PGKLEWIGR	50
INPNNGVTLY	NQKFQDKATL	TVDKSSTTAY	MELRSLTSED	SAVYYCARST	100
MITNYVMDYW	GQGTSTVTSS	AKTTPPSVYP	LAPGSAQTN	SMVTLGCLVK	150
GYFPEPVTVT	WNSGSLSSGV	HTFFAVLQSD	LYTLSSSVTV	PSSTWPSETV	200
TCNVAHPASS	TKVDKKIVPR	DSGGPSEKSE	EINEKDLRKK	SELQGTALGN	250
LKQIYYNSK	AITSEKSAD	QFLTNTLLFK	GGFTGHPWYN	DLLVDLGSTA	300
ATSEYEGSSV	DLYGAYYGQ	CAGGTPNKTA	CMYGGVTLHD	NNRLTEKKV	350
PINLWIDGKQ	TTVPIDKVKT	SKKEVTVQEL	DLQARHYLHG	KFGLYNSDSF	400
GGKVQRGLIV	FHSSEGSTVS	YDLFDAQGQY	PDTLLRIYRD	NTTISSTSLS	450
ISLYLYTT					458

Light chain / Chaîne légère / Cadena ligera

SIVMTQTPTS	LLVSAGDRV	ITCKASQSVS	NDVAWYQKQP	GQSPKLLISY	50'
TSSRYAGVPD	RFGSGYGT	FTLTSSVQA	EDAAVYFCQQ	DYNSPPTFGG	100'
GTKLEIKRAD	AAPTVSIFPP	SSEQLTSGGA	SVVCFLNNFY	PKDINVKWKI	150'
DGSRQNGVL	NSWTDQDSK	STYSMSSTLT	LTKDEYERHN	SYTCEATHKT	200'
STSPIVKSFN	RNES				214'

Disulfide bridges location / Position des ponts disulfure /
Posiciones de los puentes disulfuro
22-96 23'-88' 134'-194' 147-202 321-331

nemonoxacinum

nemonoxacin



7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

némonoxacine

acide 7-[(3S,5S)-3-amino-5-méthylpipéridin-1-yl]-1-cyclopropyl-8-méthoxy-4-oxo-1,4-dihydroquinoléine-3-carboxylique

nemonoxacino

ácido 7-[(3S,5S)-3-amino-5-metilpiperidin-1-il]-1-ciclopropil-8-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxílico

**obinepitidum**

obinepitide


[34-L-glutamine]pancreatic hormone (human)

obinépitide

[34-L-glutamine]hormone pancréatique humaine

obinepitida

[34-L-glutamina]hormona pancreática humana



H-Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp-Asn-Ala-
10
Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-
20
Arg-Arg-Tyr-Ile-Asn-Met-Leu-Thr-Arg-Gln-Arg-Tyr-NH₂
30

ozenoxacinum

ozenoxacin


1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

ozénoxacine

acide 1-cyclopropyl-8-méthyl-7-[5-méthyl-6-(méthylamino)pyridin-3-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique

ozenoxacino

ácido 1-ciclopropil-7-[5-metil-6-(metilamino)piridin-3-il]-8-metil-4-oxo-1,4-dihidroquinolina-3-carboxílico

 $C_{21}H_{21}N_3O_3$ **padeliporfinum**


padeliporfin

dihydrogen (3-((7*S*,8*S*,17*R*,18*R*)-13-acetyl-18-ethyl-5-(2-methoxy-2-oxoethyl)-2,8,12,17-tetramethyl-3-[(2-sulfonatoethyl)carbamoyl]-7,8,17,18-tetrahydroporphyrin-7-yl)propanoato)palladium

padéliporfine

dihydrogène(3-((7*S*,8*S*,17*R*,18*R*)-13-acétyl-18-éthyl-5-(2-méthoxy-2-oxoéthyl)-2,8,12,17-tétraméthyl-3-[(2-sulfonatoéthyl)carbamoyl]-7,8,17,18-tétrahydroporphirin-7-yl)propanoato)palladium

padeliporfina

dihidrógeno(3-((7*S*,8*S*,17*R*,18*R*)-13-acetil-18-etil-5-(2-metoxi-2-oxoetil)-2,8,12,17-tetrametil-3-[(2-sulfonatoetil)carbamoil]-7,8,17,18-tetrahidroporfirin-7-il)propanoato)paladio $C_{37}H_{43}N_5O_9PdS$ **pamapimodum**

pamapimod



6-(2,4-difluorophenoxy)-2-[(1,5-dihydroxypentan-3-yl)amino]-8-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one

pamapimod

6-(2,4-difluorophénoxy)-2-[(1,5-dihydroxypentan-3-yl)amino]-8-méthylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one

pamapimod

6-(2,4-difluorofenoxi)-2-[(1,5-dihidroxipentan-3-il)amino]-8-metilpirido[2,3-*d*]pirimidin-7(8*H*)-ona

**panobinostat**



panobinostat

(2*E*)-*N*-hydroxy-3-[4-({[2-(2-méthyl-1*H*-indol-3-yl)éthyl]amino}méthyl)phényl]prop-2-énamide

panobinostat

(2*E*)-*N*-hydroxy-3-[4-({[2-(2-méthyl-1*H*-indol-3-yl)éthyl]amino}méthyl)phényl]prop-2-énamide

panobinostat

(2*E*)-*N*-hidroxi-3-[4-({[2-(2-metil-1*H*-indol-3-il)etil]amino}metil)fenil]prop-2-enamida**pardoprunoxum**



pardoprunox

7-(4-methylpiperazin-1-yl)-1,3-benzoxazol-2(3*H*)-one

pardoprunox

7-(4-méthylpipérazin-1-yl)-1,3-benzoxazol-2(3*H*)-one

pardoprunox

7-(4-metilpiperazin-1-il)-1,3-benzoxazol-2(3*H*)-ona**resatorvidum**

resatorvid


ethyl (6*R*)-6-[(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate

résatorvid

(6*R*)-6-[(2-chloro-4-fluorophényl)sulfamoyl]cyclohex-1-ène-1-carboxylate d'éthyle

resatorvid

(6*R*)-6-[(2-cloro-4-fluorofenil)sulfamoil]ciclohex-1-eno-1-carboxilato de etilo

$C_{15}H_{17}ClFNO_4S$ **rusalatidum**

rusalatide

human prothrombin-(508-530)-peptidamide (thrombin heavy chain fragment (TRAP 508))

rusalatide

prothrombine humaine-(508-530)-peptidamide (fragment de la chaîne lourde de la thrombine (TRAP 508))

rusalatida

protrombina humana-(508-530)-peptidamida (fragmento de la cadena pesada de la trombina (TRAP 508))

 $C_{97}H_{147}N_{29}O_{35}S$

H-Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-
 10
 Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-NH₂
 20

senicapocum

senicapoc


2,2-bis(4-fluorophenyl)-2-phenylacetamide

sénicapoc

2,2-bis(4-fluorophényl)-2-phénylacétamide

senicapoc

2-fenil-2,2-bis(4-fluorofenil)acetamida

 $C_{20}H_{15}F_2NO$ **tanespimycinum**

tanespimycin


(4*E*,6*Z*,8*S*,9*S*,10*E*,12*S*,13*R*,14*S*,16*R*)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-[(prop-2-en-1-yl)amino]-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

tanespimicine

carbamate de (4*E*,6*Z*,8*S*,9*S*,10*E*,12*S*,13*R*,14*S*,16*R*)-13-hydroxy-8,14-diméthoxy-4,10,12,16-tétraméthyl-3,20,22-trioxo-19-[(prop-2-én-1-yl)amino]-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaén-9-yle

tanespimicina

carbamato de (4*E*,6*Z*,8*S*,9*S*,10*E*,12*S*,13*R*,14*S*,16*R*)-13-hidroxi-8,14-dimetoxi-4,10,12,16-tetrametil-3,20,22-trioxo-19-[(prop-2-en-1-il)amino]-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-ilo

$C_{31}H_{43}N_3O_8$ **telatinibum**


telatinib

4-[(4-[(4-chlorophenyl)amino]furo[2,3-*d*]pyridazin-7-yl)oxy)methyl]-*N*-methylpyridine-2-carboxamide

télatinib

4-[(4-[(4-chlorophényl)amino]furo[2,3-*d*]pyridazin-7-yl)oxy)méthyl]-*N*-méthylpyridine-2-carboxamide

telatinib

4-[(4-[(4-clorofenil)amino]furo[2,3-*d*]piridazin-7-il)oxi)metil]-*N*-metilpiridina-2-carboxamida $C_{20}H_{16}ClN_5O_3$ **tesamorelinum**


tesamorelin

(3*E*)-hex-3-enoylsomatoliberin (human GHRH)

tésamoréline

(3*E*)-hex-3-enoylsomatolibérine humaine

tesamorelina

(3*E*)-hex-3-enoilsomatoliberina humana $C_{221}H_{366}N_{72}O_{67}S$ **ulipristalum**

ulipristal



11β-[4-(dimethylamino)phenyl]-17-hydroxy-19-norpregna-4,9-diene-3,20-dione

ulipristal

11β-[4-(diméthylamino)phényl]-17-hydroxy-19-norprégna-4,9-diène-3,20-dione

ulipristal

11β-[4-(dimetilamino)fenil]-17-hidroxi-19-norpregna-4,9-dieno-3,20-diona



vernakalantum
vernakalant



(3*R*)-1-[(1*R*,2*R*)-2-[2-(3,4-dimethoxyphenyl)ethoxy]=
cyclohexyl]pyrrolidin-3-ol

vernakalant

(3*R*)-1-[(1*R*,2*R*)-2-[2-(3,4-diméthoxyphényl)éthoxy]=
cyclohexyl]pyrrolidin-3-ol

vernakalant

(3*R*)-1-[(1*R*,2*R*)-2-[2-(3,4-dimetoxifenil)etoxi]ciclohexil]pirrolidin-3-ol



votucalisum*
votucalis


methionyl[145-leucine]FS-HBP2 (*Rhipicephalus appendiculatus*
(Brown ear tick) Female-Specific Histamine-Binding Protein 2)

votucalis

méthionyl[145-leucine]FS-HBP2 (Protéine 2 se liant à l'histamine
spécifique à la tique femelle *Rhipicephalus appendiculatus*)

votucalis

metionil[145-leucina]FS-HBP2 (Proteína 2 que se une a la histamina
específica de la garrapata hembra *Rhipicephalus appendiculatus*)



					M
NQPDWADEAA	NGAHQDAWKS	LKADVENVYY	MVKATYKNDP	VWGNDFTCVG	50
VMANDVNEDE	KSIQAEFLFM	NNADTNMQFA	TEKVTAVKMY	GYNRENAFRY	100
ETEDGQVFTD	VIAYSDDNCD	VIYVPGTDGN	EEGYELWTTD	YDNILANCLN	150
KFNEYAVGRE	TRDVFTSACL	E			171


Disulfide bridges location / Position des ponts disulfure /
Posiciones de los puentes disulfuro
48-169 119-148

**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Nonproprietary Names (Rec. INN): List 14
(WHO Chronicle, Vol. 28, No. 10, 1974)

p. 4 **dimemorfanum**
dimemorfan


insert the following graphic formula:



Dénominations communes internationales recommandées (DCI Rec.): Liste 14
(Chronique OMS, Vol. 28, No. 10, 1974)

p. 4 **dimemorfanum**
dimémorfane


insérer la formule développée suivante:



Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 14
(Crónica de la OMS, Vol. 28, No. 10, 1974)

p. 4 **dimemorfanum**
dimemorfano

insértese la fórmula desarrollada siguiente:



Recommended International Nonproprietary Names (Rec. INN): List 34
Dénominations communes internationales recommandées (DCI Rec.): Liste 34
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 34
(WHO Drug Information, Vol. 8, No. 3, 1994)

p. 167	<i>suprimáse</i>	<i>insértese</i>
	afovirseno	afovirsén

Recommended International Nonproprietary Names (Rec. INN): List 37
Dénominations communes internationales recommandées (DCI Rec.): Liste 37
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 37
(WHO Drug Information, Vol. 11, No. 1, 1997)

p. 41	<i>suprimáse</i>	<i>insértese</i>
	fomivirseno	fomivirsén

Recommended International Nonproprietary Names (Rec. INN): List 39
Dénominations communes internationales recommandées (DCI Rec.): Liste 39
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 39
(WHO Drug Information, Vol. 12, No. 1, 1998)

p. 57	<i>suprimáse</i>	<i>insértese</i>
	trecovirseno	trecovirsén

Recommended International Nonproprietary Names (Rec. INN): List 47
Dénominations communes internationales recommandées (DCI Rec.): Liste 47
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 47
(WHO Drug Information, Vol. 16, No. 1, 2002)

p. 84	<i>suprimáse</i>	<i>insértese</i>
	alicaforseno	alicaforsén

Recommended International Nonproprietary Names (Rec. INN): List 49
Dénominations communes internationales recommandées (DCI Rec.): Liste 49
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 49
(WHO Drug Information, Vol. 17, No. 2, 2003)

p. 129	<i>suprimáse</i>	<i>insértese</i>
	oblimerseno	oblimersén

Recommended International Nonproprietary Names (Rec. INN): List 51
Dénominations communes internationales recommandées (DCI Rec.): Liste 51
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 51
(WHO Drug Information, Vol. 18, No. 1, 2004)

p. 85	<i>suprimáse</i>	<i>insértese</i>
	aprinocarseno	aprinocarsén

Recommended International Nonproprietary Names (Rec. INN): List 57**Dénominations communes internationales recommandées (DCI Rec.): Liste 57****Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 57**
(WHO Drug Information, Vol. 21, No. 1, 2007)p. 55 **aclidinii bromidum**

bromuro de aclidinio

sustitúyase el nombre químico por el siguiente:

bromuro de (3R)-1-(3-fenoxipropil)-3-[(hidroxibis(tiofen-2-il)acetiloxi)]-1-2-butil-3-[4-[3-(dibutilamino)propil]benzoil]-1 λ^5 -azabicyclo[2.2.2]octan-1-ilio

* Electronic structure available on Mednet: <http://mednet.who.int/>* Structure électronique disponible sur Mednet: <http://mednet.who.int/>* Estructura electrónica disponible en Mednet: <http://mednet.who.int/>**Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales**

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.